Estech announced that the first three patients have been enrolled in the HISTORIC-AF European multicentre staged hybrid ablation clinical study. Ten centres will participate in the study which is expected to enrol over 100 patients in Italy, Germany, the United Kingdom, France, and Poland.
The HISTORIC-AF staged hybrid ablation study will enrol persistent and long-standing persistent atrial fibrillation (AF) patients who represent over 50% of all AF patients in a two-step procedure. The first stage is a true minimally invasive endoscopic epicardial ablation utilising the COBRA Adhere XL device (Estech) to isolate the posterior left atrium via the highly efficacious box lesion. This unilateral procedure usually lasts less than two hours and is concluded with rigorous electrophysiological confirmation of conduction block in the operating or hybrid suite. A continuous loop monitor is implanted to continuously monitor the electrical activity of the heart. Four to six weeks later, the second stage is performed in the electrophysiology lab utilising electrophysiological mapping and, if necessary, additional endocardial catheter ablation.
The HISTORIC-AF clinical study follows the extensive experience with this staged hybrid approach accumulated by professor Claudio Muneretto, and Antonio Curnis, Civil Hospital of the University of Brescia Medical School, Italy. “We now have experience with almost 50 patients using this technology in a staged hybrid approach, and are very pleased with the safety and the results,” stated Professor Muneretto. “Teamwork between cardiac surgery and electrophysiology will be the key for successful treatment of this challenging disease. Our data indicate that even for the most difficult long-standing persistent AF patients, we have better than 85% freedom from AF throughout more than two years’ follow-up, confirmed by implanted continuous loop recorder data. We have found that the staged approach provides superior clinical success and more efficient workflow. Our patients are very happy with their clinical outcomes and with this treatment,” Muneretto concluded.
“We are excited about the staged hybrid solution with the Estech platform which offers us many potential advantages, including a more comprehensive lesion set, better lesion assessment, shorter procedure times for each discipline, fewer complications, and ultimately better outcomes. This will allow us to treat a large population of AF patients previously thought unsuitable for catheter or surgical ablation alone,” Curnis added.